The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of ...
Clinical Trials Arena on MSN
BMS reports positive data from phase II QUINTESSENTIAL study for r/r MM
The multi-centre, single-arm, open-label study achieved its primary endpoint.
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has learned. | Novartis and Bristol Myers Squibb have halted ...
Large pharmaceutical firm Novartis confirmed that it is halting and investigating several clinical trial programs involving ...
ZincFive launches its purpose-built NiZn BMS, delivering simpler deployment, stronger cybersecurity, and more intelligent ...
Bristol Myers Squibb, the US pharma major, has reported positive topline Phase II results for arlocabtagene autoleucel (arlo-cel; BMS-986393), an investigational GPRC5D-directed CAR T cell therapy, in ...
After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results